Supported by our 650 employees we develop and manufacture
active ingredients and pharmaceuticals to the highest international standards.

Since 2008, we have been a subsidiary of
FAREVA Group, which operates in 13 countries and has 43 production sites and 15 research and development centers around the world.

One of our key focus is on developing and manufacturing products for cancer treatment and immunosuppressive therapies.